286 results on '"A. Druzd-Sitek"'
Number of results to display per page
Search Results
2. Identification of novel genetic loci for risk of multiple myeloma by functional annotation
- Author
-
Macauda, Angelica, Briem, Klara, Clay-Gilmour, Alyssa, Cozen, Wendy, Försti, Asta, Giaccherini, Matteo, Corradi, Chiara, Sainz, Juan, Niazi, Yasmeen, ter Horst, Rob, Li, Yang, Netea, Mihai G., Vogel, Ulla, Hemminki, Kari, Slager, Susan L., Varkonyi, Judit, Andersen, Vibeke, Iskierka-Jazdzewska, Elzbieta, Mártinez-Lopez, Joaquin, Zaucha, Jan, Camp, Nicola J., Rajkumar, S. Vincent, Druzd-Sitek, Agnieszka, Bhatti, Parveen, Chanock, Stephen J., Kumar, Shaji K., Subocz, Edyta, Mazur, Grzegorz, Landi, Stefano, Machiela, Mitchell J., Jerez, Andrés, Norman, Aaron D., Hildebrandt, Michelle A. T., Kadar, Katalin, Berndt, Sonja I., Ziv, Elad, Buda, Gabriele, Nagler, Arnon, Dumontet, Charles, Raźny, Malgorzata, Watek, Marzena, Butrym, Aleksandra, Grzasko, Norbert, Dudzinski, Marek, Rybicka-Ramos, Malwina, Matera, Eva-Laure, García-Sanz, Ramón, Goldschmidt, Hartmut, Jamroziak, Krzysztof, Jurczyszyn, Artur, Clavero, Esther, Giles, Graham G., Pelosini, Matteo, Zawirska, Daria, Kruszewski, Marcin, Marques, Herlander, Haastrup, Eva, Sánchez-Maldonado, José Manuel, Bertsch, Uta, Rymko, Marcin, Raab, Marc-Steffen, Brown, Elizabeth E., Hofmann, Jonathan N., Vachon, Celine, Campa, Daniele, and Canzian, Federico
- Published
- 2023
- Full Text
- View/download PDF
3. Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
- Author
-
Kubicki, Tadeusz, Dytfeld, Dominik, Barnidge, David, Sakrikar, Dhananjay, Przybyłowicz-Chalecka, Anna, Jamroziak, Krzysztof, Robak, Paweł, Czyż, Jarosław, Tyczyńska, Agata, Druzd-Sitek, Agnieszka, Giannopoulos, Krzysztof, Wróbel, Tomasz, Nowicki, Adam, Szczepaniak, Tomasz, Łojko-Dankowska, Anna, Matuszak, Magdalena, Gil, Lidia, Puła, Bartosz, Szukalski, Łukasz, Końska, Agnieszka, Zaucha, Jan Maciej, Walewski, Jan, Mikulski, Damian, Czabak, Olga, Robak, Tadeusz, Jiang, Ken, Cooperrider, Jennifer H., Jakubowiak, Andrzej J., and Derman, Benjamin A.
- Published
- 2024
- Full Text
- View/download PDF
4. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
- Author
-
Dytfeld, Dominik, Wróbel, Tomasz, Jamroziak, Krzysztof, Kubicki, Tadeusz, Robak, Paweł, Walter-Croneck, Adam, Czyż, Jarosław, Tyczyńska, Agata, Druzd-Sitek, Agnieszka, Giannopoulos, Krzysztof, Nowicki, Adam, Szczepaniak, Tomasz, Łojko-Dankowska, Anna, Matuszak, Magdalena, Gil, Lidia, Puła, Bartosz, Rybka, Justyna, Majcherek, Maciej, Usnarska-Zubkiewicz, Lidia, Szukalski, Łukasz, Końska, Agnieszka, Zaucha, Jan Maciej, Walewski, Jan, Mikulski, Damian, Czabak, Olga, Robak, Tadeusz, Lahoud, Oscar B, Zonder, Jeffrey A, Griffith, Kent, Stefka, Andrew, Major, Ajay, Derman, Benjamin A, and Jakubowiak, Andrzej J
- Published
- 2023
- Full Text
- View/download PDF
5. High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
- Author
-
Joanna Romejko-Jarosinska, Beata Ostrowska, Anna Dabrowska-Iwanicka, Katarzyna Domanska-Czyz, Grzegorz Rymkiewicz, Ewa Paszkiewicz-Kozik, Robert Konecki, Anna Borawska, Agnieszka Druzd-Sitek, Elzbieta Lampka, Wlodzimierz Osiadacz, Michal Osowiecki, Lidia Popławska, Monika Swierkowska, Lukasz Targonski, Joanna Tajer, Grazyna Lapinska, Malwina Smorczewska, and Jan Walewski
- Subjects
Medicine ,Science - Abstract
Abstract Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85–95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggressive B-cell lymphoma GMALL/B-ALL/NHL2002 including 6 cycles of alternating immunochemotherapy with intermediate-dose methotrexate in each cycle, and reduced total doxorubicin dose (100 mg/m2 for whole treatment). Majority of patients (77%) received consolidative radiotherapy. A median (range) age of patients was 30 (18–59) years, and 60% were female. With a median (range) follow up of 9 (1–17) years, 5-year overall survival (OS) and 5-year progression free survival (PFS) were 94% and 92%, respectively. Positron emission tomography—computed tomography (PET-CT) results at the end of chemotherapy were predictive for outcome: OS and PFS at 5 year were 96% and 94% in PET-CT negative patients, respectively, and 70% and 70% in PET-CT-positive patients (p = 0.004 for OS, p = 0.01 for PFS). Eight (6%) patients had recurrent/refractory disease, however, no central nervous system (CNS) relapse was observed. Acute toxicity included pancytopenia grade 3/4, neutropenic fever, and treatment related mortality rate of 0.8%. Second malignancies and late cardiotoxicity occurred in 2.4% and 2.4% of patients, respectively. Intensive alternating immunochemotherapy protocol GMALL/B-ALL/NHL2002 is curative for more than 90% of PMBL patients and late toxicity in young patients is moderated. The attenuated dose of doxorubicin and intermediate dose of methotrexate may contribute to low incidence of late cardiotoxicity and effective CNS prophylaxis.
- Published
- 2022
- Full Text
- View/download PDF
6. A polygenic risk score for multiple myeloma risk prediction
- Author
-
Canzian, Federico, Piredda, Chiara, Macauda, Angelica, Zawirska, Daria, Andersen, Niels Frost, Nagler, Arnon, Zaucha, Jan Maciej, Mazur, Grzegorz, Dumontet, Charles, Wątek, Marzena, Jamroziak, Krzysztof, Sainz, Juan, Várkonyi, Judit, Butrym, Aleksandra, Beider, Katia, Abildgaard, Niels, Lesueur, Fabienne, Dudziński, Marek, Vangsted, Annette Juul, Pelosini, Matteo, Subocz, Edyta, Petrini, Mario, Buda, Gabriele, Raźny, Małgorzata, Gemignani, Federica, Marques, Herlander, Orciuolo, Enrico, Kadar, Katalin, Jurczyszyn, Artur, Druzd-Sitek, Agnieszka, Vogel, Ulla, Andersen, Vibeke, Reis, Rui Manuel, Suska, Anna, Avet-Loiseau, Hervé, Kruszewski, Marcin, Tomczak, Waldemar, Rymko, Marcin, Minvielle, Stephane, and Campa, Daniele
- Published
- 2022
- Full Text
- View/download PDF
7. High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
- Author
-
Romejko-Jarosinska, Joanna, Ostrowska, Beata, Dabrowska-Iwanicka, Anna, Domanska-Czyz, Katarzyna, Rymkiewicz, Grzegorz, Paszkiewicz-Kozik, Ewa, Konecki, Robert, Borawska, Anna, Druzd-Sitek, Agnieszka, Lampka, Elzbieta, Osiadacz, Wlodzimierz, Osowiecki, Michal, Popławska, Lidia, Swierkowska, Monika, Targonski, Lukasz, Tajer, Joanna, Lapinska, Grazyna, Smorczewska, Malwina, and Walewski, Jan
- Published
- 2022
- Full Text
- View/download PDF
8. Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.
- Author
-
Charliński, Grzegorz, Grząśko, Norbert, Bołkun, Łukasz, Sawicki, Waldemar, Paczkowska, Edyta, Druzd-Sitek, Agnieszka, Usnarska-Zubkiewicz, Lidia, Butrym, Aleksandra, Wiater, Elżbieta, Boguradzki, Piotr, Budziszewska, Bożena, Wojciechowska, Małgorzata, Mordak-Domagała, Monika, and Jurczyszyn, Artur
- Abstract
Introduction: Therapeutic adherence (TA) is one of the most important factors influencing the effectiveness of treatment. Oral anti-cancer drugs are increasingly used to treat malignancy including multiple myeloma (MM). Our study aimed to determine TA of patients with MM treated with IMiDs, to identify TA risk factors, and to determine satisfaction with medical care during the treatment with IMiDs. Methods: A cross-sectional survey-based study involving adult patients with MM treated with IMiDs. Results: Between January 2021 and May 2021, 267 patients with MM were enrolled in the study. The dosing schedule was declared as easy by 71.8% of patients, as standard for 24.0%, and difficult for 4.2% of patients. During MM treatment, 85.0% of patients did not skip any IMiDs dose, and 87.6% did not skip the IMiDs dose in the last cycle of chemotherapy. Identified factors affecting TA included the treatment duration and education level. In addition, depending on the patient's well-being, gender, and household companionship influenced TA. Satisfaction with medical care during the treatment with IMiDs was declared by 95.5% of patients with MM. In our cohort, 95.5% of patients were satisfied with the information they received from the hematologist during treatment with IMiDs. Conclusions: Patients with MM treated with IMiDs are highly adherent to treatment. With time from the beginning of treatment, patients need more attention and motivation to adhere to the therapy rules. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone
- Author
-
Kubicki, Tadeusz, primary, Jamroziak, Krzysztof, additional, Robak, Paweł, additional, Czyż, Jarosław, additional, Tyczyńska, Agata, additional, Druzd-Sitek, Agnieszka, additional, Giannopoulos, Krzysztof, additional, Wróbel, Tomasz, additional, Nowicki, Adam, additional, Szczepaniak, Tomasz, additional, Łojko-Dankowska, Anna, additional, Matuszak, Magdalena, additional, Gil, Lidia, additional, Puła, Bartosz, additional, Szukalski, Łukasz, additional, Końska, Agnieszka, additional, Zaucha, Jan M., additional, Walewski, Jan, additional, Mikulski, Damian, additional, Czabak, Olga, additional, Robak, Tadeusz, additional, Kruk-Kwapisz, Dorota, additional, Derman, Benjamin A., additional, Major, Ajay, additional, Jakubowiak, Andrzej J., additional, and Dytfeld, Dominik, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Genetically determined telomere length and multiple myeloma risk and outcome
- Author
-
Matteo Giaccherini, Angelica Macauda, Enrico Orciuolo, Marcin Rymko, Karolina Gruenpeter, Charles Dumontet, Malgorzata Raźny, Victor Moreno, Gabriele Buda, Katia Beider, Judit Varkonyi, Hervé Avet-Loiseau, Joaquín Martinez-Lopez, Herlander Marques, Marzena Watek, Maria Eugenia Sarasquete, Vibeke Andersen, Lionel Karlin, Anna Suska, Marcin Kruszewski, Niels Abildgaard, Marek Dudziński, Aleksandra Butrym, Arnold Nagler, Annette Juul Vangsted, Katalin Kadar, Tomczak Waldemar, Krzysztof Jamroziak, Svend Erik Hove Jacobsen, Lene Hyldahl Ebbesen, Michał Taszner, Grzegorz Mazur, Fabienne Lesueur, Matteo Pelosini, Ramon Garcia-Sanz, Artur Jurczyszyn, Delphine Demangel, Rui Manuel Reis, Elżbieta Iskierka-Jażdżewska, Miroslaw Markiewicz, Federica Gemignani, Edyta Subocz, Daria Zawirska, Agnieszka Druzd-Sitek, Anna Stępień, M. Henar Alonso, Juan Sainz, Federico Canzian, and Daniele Campa
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM). However, LTL measurement is prone to heterogeneity due to sample handling and study design (retrospective vs. prospective). LTL is genetically determined; genome-wide association studies identified 11 SNPs that, combined in a score, can be used as a genetic instrument to measure LTL and evaluate its association with MM risk. This approach has been already successfully attempted in various cancer types but never in MM. We tested the “teloscore” in 2407 MM patients and 1741 controls from the International Multiple Myeloma rESEarch (IMMeNSE) consortium. We observed an increased risk for longer genetically determined telomere length (gdTL) (OR = 1.69; 95% CI 1.36–2.11; P = 2.97 × 10−6 for highest vs. lowest quintile of the score). Furthermore, in a subset of 1376 MM patients we tested the relationship between the teloscore and MM patients survival, observing a better prognosis for longer gdTL compared with shorter gdTL (HR = 0.93; 95% CI 0.86–0.99; P = 0.049). In conclusion, we report convincing evidence that longer gdTL is a risk marker for MM risk, and that it is potentially involved in increasing MM survival.
- Published
- 2021
- Full Text
- View/download PDF
11. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
- Author
-
Esther Clavero, José Manuel Sanchez-Maldonado, Angelica Macauda, Rob Ter Horst, Belém Sampaio-Marques, Artur Jurczyszyn, Alyssa Clay-Gilmour, Angelika Stein, Michelle A. T. Hildebrandt, Niels Weinhold, Gabriele Buda, Ramón García-Sanz, Waldemar Tomczak, Ulla Vogel, Andrés Jerez, Daria Zawirska, Marzena Wątek, Jonathan N. Hofmann, Stefano Landi, John J. Spinelli, Aleksandra Butrym, Abhishek Kumar, Joaquín Martínez-López, Sara Galimberti, María Eugenia Sarasquete, Edyta Subocz, Elzbieta Iskierka-Jażdżewska, Graham G. Giles, Malwina Rybicka-Ramos, Marcin Kruszewski, Niels Abildgaard, Francisco García Verdejo, Pedro Sánchez Rovira, Miguel Inacio da Silva Filho, Katalin Kadar, Małgorzata Razny, Wendy Cozen, Matteo Pelosini, Manuel Jurado, Parveen Bhatti, Marek Dudzinski, Agnieszka Druzd-Sitek, Enrico Orciuolo, Yang Li, Aaron D. Norman, Jan Maciej Zaucha, Rui Manuel Reis, Miroslaw Markiewicz, Juan José Rodríguez Sevilla, Vibeke Andersen, Krzysztof Jamroziak, Kari Hemminki, Sonja I. Berndt, Vicent Rajkumar, Grzegorz Mazur, Shaji K. Kumar, Paula Ludovico, Arnon Nagler, Stephen J. Chanock, Charles Dumontet, Mitchell J. Machiela, Judit Varkonyi, Nicola J. Camp, Elad Ziv, Annette Juul Vangsted, Elizabeth E. Brown, Daniele Campa, Celine M. Vachon, Mihai G. Netea, Federico Canzian, Asta Försti, and Juan Sainz
- Subjects
multiple myeloma ,autophagy ,genetic variants ,genetic susceptibility ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10−9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10−4−5.79 × 10−14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10−4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 × 10−4) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 × 10−4). We also found that the CD46rs1142469 SNP correlated with numbers of CD19+ B cells, CD19+CD3− B cells, CD5+IgD− cells, IgM− cells, IgD−IgM− cells, and CD4−CD8− PBMCs (p = 4.9 × 10−4−8.6 × 10−4) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2Ars2811710 SNP correlated with levels of CD4+EMCD45RO+CD27− cells (p = 9.3 × 10−4). These results suggest that genetic variants within these six loci influence MM risk through the modulation of specific subsets of immune cells, as well as vitamin D3−, MCP-2−, and IL20-dependent pathways.
- Published
- 2023
- Full Text
- View/download PDF
12. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
- Author
-
Kubicki, Tadeusz, Jamroziak, Krzysztof, Robak, Paweł, Czyż, Jarosław, Tyczyńska, Agata, Druzd-Sitek, Agnieszka, Giannopoulos, Krzysztof, Wróbel, Tomasz, Nowicki, Adam, Szczepaniak, Tomasz, Łojko-Dankowska, Anna, Matuszak, Magdalena, Gil, Lidia, Puła, Bartosz, Szukalski, Łukasz, Końska, Agnieszka, Zaucha, Jan M., Walewski, Jan, Mikulski, Damian, and Czabak, Olga
- Published
- 2024
- Full Text
- View/download PDF
13. Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a “real-world” study: Experiences of the Polish Myeloma Group
- Author
-
Charliński, Grzegorz, primary, Grząśko, Norbert, additional, Bołkun, Łukasz, additional, Sawicki, Waldemar, additional, Paczkowska, Edyta, additional, Druzd-Sitek, Agnieszka, additional, Usnarska-Zubkiewicz, Lidia, additional, Butrym, Aleksandra, additional, Wiater, Elżbieta, additional, Boguradzki, Piotr, additional, Budziszewska, Bożena, additional, Wojciechowska, Małgorzata, additional, Mordak-Domagała, Monika, additional, and Jurczyszyn, Artur, additional
- Published
- 2023
- Full Text
- View/download PDF
14. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
- Author
-
Kubicki, Tadeusz, primary, Dytfeld, Dominik, additional, Wróbel, Tomasz, additional, Jamroziak, Krzysztof, additional, Robak, Paweł, additional, Czyż, Jarosław, additional, Tyczyńska, Agata, additional, Druzd‐Sitek, Agnieszka, additional, Giannopoulos, Krzysztof, additional, Szczepaniak, Tomasz, additional, Łojko‐Dankowska, Anna, additional, Matuszak, Magdalena, additional, Gil, Lidia, additional, Puła, Bartosz, additional, Rybka, Justyna, additional, Majcherek, Maciej, additional, Usnarska‐Zubkiewicz, Lidia, additional, Szukalski, Łukasz, additional, Zaucha, Jan Maciej, additional, Mikulski, Damian, additional, Czabak, Olga, additional, Lahoud, Oscar B., additional, Stefka, Andrew, additional, Derman, Benjamin A., additional, and Jakubowiak, Andrzej J., additional
- Published
- 2023
- Full Text
- View/download PDF
15. Genetically determined telomere length and multiple myeloma risk and outcome
- Author
-
Giaccherini, Matteo, Macauda, Angelica, Orciuolo, Enrico, Rymko, Marcin, Gruenpeter, Karolina, Dumontet, Charles, Raźny, Malgorzata, Moreno, Victor, Buda, Gabriele, Beider, Katia, Varkonyi, Judit, Avet-Loiseau, Hervé, Martinez-Lopez, Joaquín, Marques, Herlander, Watek, Marzena, Sarasquete, Maria Eugenia, Andersen, Vibeke, Karlin, Lionel, Suska, Anna, Kruszewski, Marcin, Abildgaard, Niels, Dudziński, Marek, Butrym, Aleksandra, Nagler, Arnold, Vangsted, Annette Juul, Kadar, Katalin, Waldemar, Tomczak, Jamroziak, Krzysztof, Jacobsen, Svend Erik Hove, Ebbesen, Lene Hyldahl, Taszner, Michał, Mazur, Grzegorz, Lesueur, Fabienne, Pelosini, Matteo, Garcia-Sanz, Ramon, Jurczyszyn, Artur, Demangel, Delphine, Reis, Rui Manuel, Iskierka-Jażdżewska, Elżbieta, Markiewicz, Miroslaw, Gemignani, Federica, Subocz, Edyta, Zawirska, Daria, Druzd-Sitek, Agnieszka, Stępień, Anna, Alonso, M. Henar, Sainz, Juan, Canzian, Federico, and Campa, Daniele
- Published
- 2021
- Full Text
- View/download PDF
16. Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine ( <scp>R‐MIV</scp> ) in patients with primary <scp>CNS</scp> lymphoma including recent <scp>COVID</scp> ‐19 pandemic experience
- Author
-
Beata Ostrowska, Katarzyna Domanska‐Czyz, Joanna Romejko‐Jarosinska, Michal Osowiecki, Lukasz Targonski, Lidia Poplawska, Robert Konecki, Martyna Kotarska, Marcin Szymanski, Anna Borawska, Monika Swierkowska, Anna Dabrowska‐Iwanicka, Agnieszka Druzd‐Sitek, Ewa Paszkiewicz‐Kozik, Ewa Mroz‐Zycinska, Joanna Tajer, Elzbieta Wojciechowska‐Lampka, Wlodzimierz Osiadacz, Grzegorz Rymkiewicz, Grazyna Lapinska, Marta Wojewodzka‐Mirocha, Wojciech Michalski, and Jan Walewski
- Subjects
Hematology - Published
- 2023
17. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
- Author
-
Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter-Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B Lahoud, Jeffrey A Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A Derman, and Andrzej J Jakubowiak
- Subjects
Oncology - Published
- 2023
18. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study
- Author
-
Paszkiewicz‐Kozik, E., primary, Kurlapski, M., additional, Swoboda, R., additional, Subocz, E., additional, Szymanski, M., additional, Taszner, M., additional, Wicherska‐Pawlowska, K., additional, Koclega, A., additional, Domanska‐Czyz, K., additional, Swierkowska, M., additional, Woszczyk, D., additional, Targonski, L., additional, Chmielowska, E., additional, Dabrowska‐Iwanicka, A., additional, Ostrowska, B., additional, Romejko‐Jarosinska, J., additional, Kotarska, M., additional, Druzd‐Sitek, A., additional, Konecki, R., additional, Mroz‐Zycinska, E., additional, Poplawska, L., additional, Borawska, A., additional, Rybka, J., additional, Michalski, W., additional, Rybski, S., additional, Halka, J., additional, Czyz, A., additional, Giebel, S., additional, Walewski, J., additional, and Zaucha, J., additional
- Published
- 2023
- Full Text
- View/download PDF
19. Możliwości leczenia indukcyjnego chorych na szpiczaka plazmocytowego kwalifikujących się do chemioterapii wysokodawkowanej wspomaganej autologiczną transplantacją komórek krwiotwórczych a aktualne zalecenia Polskiej Grupy Szpiczakowej
- Author
-
Druzd-Sitek, Agnieszka and Walewski, Jan
- Published
- 2017
- Full Text
- View/download PDF
20. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017
- Author
-
Dmoszyńska, Anna, Usnarska-Zubkiewicz, Lidia, Walewski, Jan, Lech-Marańda, Ewa, Walter-Croneck, Adam, Pieńkowska-Grela, Barbara, Charliński, Grzegorz, Jędrzejczak, Wiesław Wiktor, Małkowski, Bogdan, Jamroziak, Krzysztof, Druzd-Sitek, Agnieszka, Dytfeld, Dominik, Komarnicki, Mieczysław, Robak, Tadeusz, Jurczyszyn, Artur, Mańko, Joanna, Skotnicki, Aleksander, Giebel, Sebastian, Wiater, Elżbieta, Czepko, Ryszard, Meder, Janusz, and Giannopoulos, Krzysztof
- Published
- 2017
- Full Text
- View/download PDF
21. A pleiotropic variant in <scp> DNAJB4 </scp> is associated with multiple myeloma risk
- Author
-
Marco Dicanio, Matteo Giaccherini, Alyssa Clay‐Gilmour, Angelica Macauda, Juan Sainz, Mitchell J. Machiela, Malwina Rybicka‐Ramos, Aaron D. Norman, Agata Tyczyńska, Stephen J. Chanock, Torben Barington, Shaji K. Kumar, Parveen Bhatti, Wendy Cozen, Elizabeth E. Brown, Anna Suska, Eva K. Haastrup, Robert Z. Orlowski, Marek Dudziński, Ramon Garcia‐Sanz, Marcin Kruszewski, Joaquin Martinez‐Lopez, Katia Beider, Elżbieta Iskierka‐Jazdzewska, Matteo Pelosini, Sonja I. Berndt, Małgorzata Raźny, Krzysztof Jamroziak, S. Vincent Rajkumar, Artur Jurczyszyn, Annette Juul Vangsted, Pilar Garrido Collado, Ulla Vogel, Jonathan N. Hofmann, Mario Petrini, Aleksandra Butrym, Susan L. Slager, Elad Ziv, Edyta Subocz, Graham G. Giles, Niels Frost Andersen, Grzegorz Mazur, Marzena Watek, Fabienne Lesueur, Michelle A. T. Hildebrandt, Daria Zawirska, Lene Hyldahl Ebbesen, Herlander Marques, Federica Gemignani, Charles Dumontet, Judit Várkonyi, Gabriele Buda, Arnon Nagler, Agnieszka Druzd‐Sitek, Xifeng Wu, Katalin Kadar, Nicola J. Camp, Norbert Grzasko, Rosalie G. Waller, Celine Vachon, Federico Canzian, and Daniele Campa
- Subjects
Cancer Research ,genetic susceptibility ,multiple myeloma ,pleiotropy ,pleiotropy scan ,polymorphisms ,Humans ,Oncogenes ,Alleles ,Phenotype ,Polymorphism, Single Nucleotide ,Genome-Wide Association Study ,Genetic Predisposition to Disease ,HSP40 Heat-Shock Proteins ,DNA-Binding Proteins ,RNA-Binding Proteins ,Multiple Myeloma ,Single Nucleotide ,Oncology ,Polymorphism - Abstract
Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits. This feature is particularly relevant in multiple myeloma (MM) because several susceptibility loci that have been identified to date are pleiotropic. Therefore, the aim of this study was to identify novel pleiotropic variants involved in MM risk using 28 684 independent single nucleotide polymorphisms (SNPs) from GWAS Catalog that reached a significant association (P < 5 × 10−8) with their respective trait. The selected SNPs were analyzed in 2434 MM cases and 3446 controls from the International Lymphoma Epidemiology Consortium (InterLymph). The 10 SNPs showing the strongest associations with MM risk in InterLymph were selected for replication in an independent set of 1955 MM cases and 1549 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and 418 MM cases and 147 282 controls from the FinnGen project. The combined analysis of the three studies identified an association between DNAJB4-rs34517439-A and an increased risk of developing MM (OR = 1.22, 95%CI 1.13-1.32, P = 4.81 × 10−7). rs34517439-A is associated with a modified expression of the FUBP1 gene, which encodes a multifunctional DNA and RNA-binding protein that it was observed to influence the regulation of various genes involved in cell cycle regulation, among which various oncogenes and oncosuppressors. In conclusion, with a pleiotropic scan approach we identified DNAJB4-rs34517439 as a potentially novel MM risk locus.
- Published
- 2022
22. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
- Author
-
Clavero, Esther, primary, Sanchez-Maldonado, José Manuel, additional, Macauda, Angelica, additional, Ter Horst, Rob, additional, Sampaio-Marques, Belém, additional, Jurczyszyn, Artur, additional, Clay-Gilmour, Alyssa, additional, Stein, Angelika, additional, Hildebrandt, Michelle A. T., additional, Weinhold, Niels, additional, Buda, Gabriele, additional, García-Sanz, Ramón, additional, Tomczak, Waldemar, additional, Vogel, Ulla, additional, Jerez, Andrés, additional, Zawirska, Daria, additional, Wątek, Marzena, additional, Hofmann, Jonathan N., additional, Landi, Stefano, additional, Spinelli, John J., additional, Butrym, Aleksandra, additional, Kumar, Abhishek, additional, Martínez-López, Joaquín, additional, Galimberti, Sara, additional, Sarasquete, María Eugenia, additional, Subocz, Edyta, additional, Iskierka-Jażdżewska, Elzbieta, additional, Giles, Graham G., additional, Rybicka-Ramos, Malwina, additional, Kruszewski, Marcin, additional, Abildgaard, Niels, additional, Verdejo, Francisco García, additional, Sánchez Rovira, Pedro, additional, da Silva Filho, Miguel Inacio, additional, Kadar, Katalin, additional, Razny, Małgorzata, additional, Cozen, Wendy, additional, Pelosini, Matteo, additional, Jurado, Manuel, additional, Bhatti, Parveen, additional, Dudzinski, Marek, additional, Druzd-Sitek, Agnieszka, additional, Orciuolo, Enrico, additional, Li, Yang, additional, Norman, Aaron D., additional, Zaucha, Jan Maciej, additional, Reis, Rui Manuel, additional, Markiewicz, Miroslaw, additional, Rodríguez Sevilla, Juan José, additional, Andersen, Vibeke, additional, Jamroziak, Krzysztof, additional, Hemminki, Kari, additional, Berndt, Sonja I., additional, Rajkumar, Vicent, additional, Mazur, Grzegorz, additional, Kumar, Shaji K., additional, Ludovico, Paula, additional, Nagler, Arnon, additional, Chanock, Stephen J., additional, Dumontet, Charles, additional, Machiela, Mitchell J., additional, Varkonyi, Judit, additional, Camp, Nicola J., additional, Ziv, Elad, additional, Vangsted, Annette Juul, additional, Brown, Elizabeth E., additional, Campa, Daniele, additional, Vachon, Celine M., additional, Netea, Mihai G., additional, Canzian, Federico, additional, Försti, Asta, additional, and Sainz, Juan, additional
- Published
- 2023
- Full Text
- View/download PDF
23. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
- Author
-
Dytfeld, Dominik, primary, Radocha, Jakub, additional, Hajek, Roman, additional, Cengiz-Seval, Guldane, additional, Berkac, Meral, additional, Coriu, Daniel, additional, Derman, Benjamin, additional, Jakubowiak, Andrzej, additional, Peceliunas, Valdas, additional, Mikkala, Gabor, additional, Bołkun, Łukasz, additional, Hawrylecka, Dorota, additional, Grosicki, Sebastian, additional, Tyczyńska, Agata, additional, Zaucha, Jan Maciej, additional, Knopińska, Wanda, additional, Semeńczuk, Grażyna, additional, Morawska, Marta, additional, Giannopoulos, Krzysztof, additional, Puła, Anna, additional, Rymko, Marcin, additional, Charliński, Grzegorz, additional, Szeremet, Agnieszka, additional, Kalicińska, Elżbieta, additional, Usnarska, Lidia, additional, Wróbel, Tomasz, additional, Jamroziak, Krzysztof, additional, Druzd-Sitek, Agnieszka, additional, Romejko Jarosińska, Joanna, additional, Sawicki, Waldemar, additional, Waszczuk-Gajda, Anna, additional, Juda, Adrian, additional, Hus, Marek, additional, and Gil, Lidia, additional
- Published
- 2023
- Full Text
- View/download PDF
24. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.
- Author
-
Clavero, E., Sanchez-Maldonado, J.M., Macauda, A., Horst, R. ter, Sampaio-Marques, B., Jurczyszyn, A., Clay-Gilmour, A., Stein, A., Hildebrandt, M.A., Weinhold, N., Buda, G., García-Sanz, R., Tomczak, W., Vogel, U., Jerez, A., Zawirska, D., Wątek, M., Hofmann, J.N., Landi, S., Spinelli, J.J., Butrym, A., Kumar, A., Martínez-López, J., Galimberti, S., Sarasquete, M.E., Subocz, E., Iskierka-Jażdżewska, E., Giles, G.G., Rybicka-Ramos, M., Kruszewski, M., Abildgaard, N., Verdejo, F.G., Sánchez Rovira, P., Silva Filho, M.I. da, Kadar, K., Razny, M., Cozen, W., Pelosini, M., Jurado, M., Bhatti, P., Dudzinski, M., Druzd-Sitek, A., Orciuolo, E., Li, Y., Norman, A.D., Zaucha, J.M., Reis, R.M., Markiewicz, M., Rodríguez Sevilla, J.J., Andersen, V., Jamroziak, K., Hemminki, K., Berndt, S.I., Rajkumar, V., Mazur, G., Kumar, S.K., Ludovico, P., Nagler, A., Chanock, S.J., Dumontet, C., Machiela, M.J., Varkonyi, J., Camp, N.J., Ziv, E., Vangsted, A.J., Brown, E.E., Campa, D., Vachon, C.M., Netea, M.G., Canzian, F., Försti, A., Sainz, J., Clavero, E., Sanchez-Maldonado, J.M., Macauda, A., Horst, R. ter, Sampaio-Marques, B., Jurczyszyn, A., Clay-Gilmour, A., Stein, A., Hildebrandt, M.A., Weinhold, N., Buda, G., García-Sanz, R., Tomczak, W., Vogel, U., Jerez, A., Zawirska, D., Wątek, M., Hofmann, J.N., Landi, S., Spinelli, J.J., Butrym, A., Kumar, A., Martínez-López, J., Galimberti, S., Sarasquete, M.E., Subocz, E., Iskierka-Jażdżewska, E., Giles, G.G., Rybicka-Ramos, M., Kruszewski, M., Abildgaard, N., Verdejo, F.G., Sánchez Rovira, P., Silva Filho, M.I. da, Kadar, K., Razny, M., Cozen, W., Pelosini, M., Jurado, M., Bhatti, P., Dudzinski, M., Druzd-Sitek, A., Orciuolo, E., Li, Y., Norman, A.D., Zaucha, J.M., Reis, R.M., Markiewicz, M., Rodríguez Sevilla, J.J., Andersen, V., Jamroziak, K., Hemminki, K., Berndt, S.I., Rajkumar, V., Mazur, G., Kumar, S.K., Ludovico, P., Nagler, A., Chanock, S.J., Dumontet, C., Machiela, M.J., Varkonyi, J., Camp, N.J., Ziv, E., Vangsted, A.J., Brown, E.E., Campa, D., Vachon, C.M., Netea, M.G., Canzian, F., Försti, A., and Sainz, J.
- Abstract
Item does not contain fulltext, Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10(-9)) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10(-4)-5.79 × 10(-14)). Mechanistically, we found that the ULK4(rs6599175) SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10(-4)), whereas the IKBKE(rs17433804) SNP correlated with the number of transitional CD24(+)CD38(+) B cells (p = 4.8 × 10(-4)) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 × 10(-4)). We also found that the CD46(rs1142469) SNP correlated with numbers of CD19(+) B cells, CD19(+)CD3(-) B cells, CD5(+)IgD(-) cells, IgM(-) cells, IgD(-)IgM(-) cells, and CD4(-)CD8(-) PBMCs (p = 4.9 × 10(-4)-8.6 × 10(-4)) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2A(rs2811710) SNP correlated with levels of CD4(+)EMCD45RO(+)CD27(-) cells (p = 9.3 × 10(-4)). These results s
- Published
- 2023
25. Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
- Author
-
Macauda, A., Briem, K., Clay-Gilmour, A., Cozen, W., Försti, A., Giaccherini, M., Corradi, C., Sainz, J., Niazi, Y., Horst, R. ter, Li, Y., Netea, M.G., Vogel, U., Hemminki, K., Slager, S.L., Varkonyi, J., Andersen, V., Iskierka-Jazdzewska, E., Mártinez-Lopez, J., Zaucha, J., Camp, N.J., Rajkumar, S.V., Druzd-Sitek, A., Bhatti, P., Chanock, S.J., Kumar, S.K., Subocz, E., Mazur, G., Landi, S., Machiela, M.J., Jerez, A., Norman, A.D., Hildebrandt, M.A., Kadar, K., Berndt, S.I., Ziv, E., Buda, G., Nagler, A., Dumontet, C., Raźny, M., Watek, M., Butrym, A., Grzasko, N., Dudzinski, M., Rybicka-Ramos, M., Matera, E.L., García-Sanz, R., Goldschmidt, H., Jamroziak, K., Jurczyszyn, A., Clavero, E., Giles, G.G., Pelosini, M., Zawirska, D., Kruszewski, M., Marques, H., Haastrup, E., Sánchez-Maldonado, J.M., Bertsch, U., Rymko, M., Raab, M.S., Brown, E.E., Hofmann, J.N., Vachon, C., Campa, D., Canzian, F., Macauda, A., Briem, K., Clay-Gilmour, A., Cozen, W., Försti, A., Giaccherini, M., Corradi, C., Sainz, J., Niazi, Y., Horst, R. ter, Li, Y., Netea, M.G., Vogel, U., Hemminki, K., Slager, S.L., Varkonyi, J., Andersen, V., Iskierka-Jazdzewska, E., Mártinez-Lopez, J., Zaucha, J., Camp, N.J., Rajkumar, S.V., Druzd-Sitek, A., Bhatti, P., Chanock, S.J., Kumar, S.K., Subocz, E., Mazur, G., Landi, S., Machiela, M.J., Jerez, A., Norman, A.D., Hildebrandt, M.A., Kadar, K., Berndt, S.I., Ziv, E., Buda, G., Nagler, A., Dumontet, C., Raźny, M., Watek, M., Butrym, A., Grzasko, N., Dudzinski, M., Rybicka-Ramos, M., Matera, E.L., García-Sanz, R., Goldschmidt, H., Jamroziak, K., Jurczyszyn, A., Clavero, E., Giles, G.G., Pelosini, M., Zawirska, D., Kruszewski, M., Marques, H., Haastrup, E., Sánchez-Maldonado, J.M., Bertsch, U., Rymko, M., Raab, M.S., Brown, E.E., Hofmann, J.N., Vachon, C., Campa, D., and Canzian, F.
- Abstract
Contains fulltext : 299996.pdf (Publisher’s version ) (Open Access), 01 november 2023
- Published
- 2023
26. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma:A Meta-Analysis of Three Large Cohorts and Functional Characterization
- Author
-
Clavero, Esther, Sanchez-Maldonado, José Manuel, Macauda, Angelica, Ter Horst, Rob, Sampaio-Marques, Belém, Jurczyszyn, Artur, Clay-Gilmour, Alyssa, Stein, Angelika, Hildebrandt, Michelle A.T., Weinhold, Niels, Buda, Gabriele, García-Sanz, Ramón, Tomczak, Waldemar, Vogel, Ulla, Jerez, Andrés, Zawirska, Daria, Wątek, Marzena, Hofmann, Jonathan N., Landi, Stefano, Spinelli, John J., Butrym, Aleksandra, Kumar, Abhishek, Martínez-López, Joaquín, Galimberti, Sara, Sarasquete, María Eugenia, Subocz, Edyta, Iskierka-Jażdżewska, Elzbieta, Giles, Graham G., Rybicka-Ramos, Malwina, Kruszewski, Marcin, Abildgaard, Niels, Verdejo, Francisco García, Sánchez Rovira, Pedro, da Silva Filho, Miguel Inacio, Kadar, Katalin, Razny, Małgorzata, Cozen, Wendy, Pelosini, Matteo, Jurado, Manuel, Bhatti, Parveen, Dudzinski, Marek, Druzd-Sitek, Agnieszka, Orciuolo, Enrico, Li, Yang, Norman, Aaron D., Zaucha, Jan Maciej, Reis, Rui Manuel, Markiewicz, Miroslaw, Rodríguez Sevilla, Juan José, Andersen, Vibeke, Jamroziak, Krzysztof, Hemminki, Kari, Berndt, Sonja I., Rajkumar, Vicent, Mazur, Grzegorz, Kumar, Shaji K., Ludovico, Paula, Nagler, Arnon, Chanock, Stephen J., Dumontet, Charles, Machiela, Mitchell J., Varkonyi, Judit, Camp, Nicola J., Ziv, Elad, Vangsted, Annette Juul, Brown, Elizabeth E., Campa, Daniele, Vachon, Celine M., Netea, Mihai G., Canzian, Federico, Försti, Asta, Sainz, Juan, Clavero, Esther, Sanchez-Maldonado, José Manuel, Macauda, Angelica, Ter Horst, Rob, Sampaio-Marques, Belém, Jurczyszyn, Artur, Clay-Gilmour, Alyssa, Stein, Angelika, Hildebrandt, Michelle A.T., Weinhold, Niels, Buda, Gabriele, García-Sanz, Ramón, Tomczak, Waldemar, Vogel, Ulla, Jerez, Andrés, Zawirska, Daria, Wątek, Marzena, Hofmann, Jonathan N., Landi, Stefano, Spinelli, John J., Butrym, Aleksandra, Kumar, Abhishek, Martínez-López, Joaquín, Galimberti, Sara, Sarasquete, María Eugenia, Subocz, Edyta, Iskierka-Jażdżewska, Elzbieta, Giles, Graham G., Rybicka-Ramos, Malwina, Kruszewski, Marcin, Abildgaard, Niels, Verdejo, Francisco García, Sánchez Rovira, Pedro, da Silva Filho, Miguel Inacio, Kadar, Katalin, Razny, Małgorzata, Cozen, Wendy, Pelosini, Matteo, Jurado, Manuel, Bhatti, Parveen, Dudzinski, Marek, Druzd-Sitek, Agnieszka, Orciuolo, Enrico, Li, Yang, Norman, Aaron D., Zaucha, Jan Maciej, Reis, Rui Manuel, Markiewicz, Miroslaw, Rodríguez Sevilla, Juan José, Andersen, Vibeke, Jamroziak, Krzysztof, Hemminki, Kari, Berndt, Sonja I., Rajkumar, Vicent, Mazur, Grzegorz, Kumar, Shaji K., Ludovico, Paula, Nagler, Arnon, Chanock, Stephen J., Dumontet, Charles, Machiela, Mitchell J., Varkonyi, Judit, Camp, Nicola J., Ziv, Elad, Vangsted, Annette Juul, Brown, Elizabeth E., Campa, Daniele, Vachon, Celine M., Netea, Mihai G., Canzian, Federico, Försti, Asta, and Sainz, Juan
- Abstract
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10−9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10−4−5.79 × 10−14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10−4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 × 10−4) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 × 10−4). We also found that the CD46rs1142469 SNP correlated with numbers of CD19+ B cells, CD19+CD3− B cells, CD5+IgD− cells, IgM− cells, IgD−IgM− cells, and CD4−CD8− PBMCs (p = 4.9 × 10−4−8.6 × 10−4)
- Published
- 2023
27. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
- Author
-
Dicanio, Marco, Giaccherini, Matteo, Clay-Gilmour, Alyssa, Macauda, Angelica, Sainz, Juan, Machiela, Mitchell J., Rybicka-Ramos, Malwina, Norman, Aaron D., Tyczyńska, Agata, Chanock, Stephen J., Barington, Torben, Kumar, Shaji K., Bhatti, Parveen, Cozen, Wendy, Brown, Elizabeth E., Suska, Anna, Haastrup, Eva K., Orlowski, Robert Z., Dudziński, Marek, Garcia-Sanz, Ramon, Kruszewski, Marcin, Martinez-Lopez, Joaquin, Beider, Katia, Iskierka-Jazdzewska, Elżbieta, Pelosini, Matteo, Berndt, Sonja I., Raźny, Małgorzata, Jamroziak, Krzysztof, Rajkumar, S. Vincent, Jurczyszyn, Artur, Vangsted, Annette Juul, Collado, Pilar Garrido, Vogel, Ulla, Hofmann, Jonathan N., Petrini, Mario, Butrym, Aleksandra, Slager, Susan L., Ziv, Elad, Subocz, Edyta, Giles, Graham G., Andersen, Niels Frost, Mazur, Grzegorz, Watek, Marzena, Lesueur, Fabienne, Hildebrandt, Michelle A.T., Zawirska, Daria, Ebbesen, Lene Hyldahl, Marques, Herlander, Gemignani, Federica, Dumontet, Charles, Várkonyi, Judit, Buda, Gabriele, Nagler, Arnon, Druzd-Sitek, Agnieszka, Wu, Xifeng, Kadar, Katalin, Camp, Nicola J., Grzasko, Norbert, Waller, Rosalie G., Vachon, Celine, Canzian, Federico, Campa, Daniele, Dicanio, Marco, Giaccherini, Matteo, Clay-Gilmour, Alyssa, Macauda, Angelica, Sainz, Juan, Machiela, Mitchell J., Rybicka-Ramos, Malwina, Norman, Aaron D., Tyczyńska, Agata, Chanock, Stephen J., Barington, Torben, Kumar, Shaji K., Bhatti, Parveen, Cozen, Wendy, Brown, Elizabeth E., Suska, Anna, Haastrup, Eva K., Orlowski, Robert Z., Dudziński, Marek, Garcia-Sanz, Ramon, Kruszewski, Marcin, Martinez-Lopez, Joaquin, Beider, Katia, Iskierka-Jazdzewska, Elżbieta, Pelosini, Matteo, Berndt, Sonja I., Raźny, Małgorzata, Jamroziak, Krzysztof, Rajkumar, S. Vincent, Jurczyszyn, Artur, Vangsted, Annette Juul, Collado, Pilar Garrido, Vogel, Ulla, Hofmann, Jonathan N., Petrini, Mario, Butrym, Aleksandra, Slager, Susan L., Ziv, Elad, Subocz, Edyta, Giles, Graham G., Andersen, Niels Frost, Mazur, Grzegorz, Watek, Marzena, Lesueur, Fabienne, Hildebrandt, Michelle A.T., Zawirska, Daria, Ebbesen, Lene Hyldahl, Marques, Herlander, Gemignani, Federica, Dumontet, Charles, Várkonyi, Judit, Buda, Gabriele, Nagler, Arnon, Druzd-Sitek, Agnieszka, Wu, Xifeng, Kadar, Katalin, Camp, Nicola J., Grzasko, Norbert, Waller, Rosalie G., Vachon, Celine, Canzian, Federico, and Campa, Daniele
- Abstract
Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits. This feature is particularly relevant in multiple myeloma (MM) because several susceptibility loci that have been identified to date are pleiotropic. Therefore, the aim of this study was to identify novel pleiotropic variants involved in MM risk using 28 684 independent single nucleotide polymorphisms (SNPs) from GWAS Catalog that reached a significant association (P < 5 × 10−8) with their respective trait. The selected SNPs were analyzed in 2434 MM cases and 3446 controls from the International Lymphoma Epidemiology Consortium (InterLymph). The 10 SNPs showing the strongest associations with MM risk in InterLymph were selected for replication in an independent set of 1955 MM cases and 1549 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and 418 MM cases and 147 282 controls from the FinnGen project. The combined analysis of the three studies identified an association between DNAJB4-rs34517439-A and an increased risk of developing MM (OR = 1.22, 95%CI 1.13-1.32, P = 4.81 × 10−7). rs34517439-A is associated with a modified expression of the FUBP1 gene, which encodes a multifunctional DNA and RNA-binding protein that it was observed to influence the regulation of various genes involved in cell cycle regulation, among which various oncogenes and oncosuppressors. In conclusion, with a pleiotropic scan approach we identified DNAJB4-rs34517439 as a potentially novel MM risk locus.
- Published
- 2023
28. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
- Author
-
European Commission, Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Dietmar Hopp Foundation, Federal Ministry of Education and Research (Germany), Fundação para a Ciência e a Tecnologia (Portugal), Clavero, Esther, Sanchez-Maldonado, José Manuel, Macauda, Angélica, Ter Horst, Rob, Sampaio-Marques, Belém, Jurczyszyn, Artur, Clay-Gilmour, Alyssa, Stein, Angelika, Hildebrandt, Michelle A. T., Weinhold, Niels, Buda, Gabriele, García-Sanz, Ramón, Tomczak, Waldemar, Vogel, Ulla, Jerez, Andrés, Zawirska, Daria, Wątek, Marzena, Hofmann, Jonathan N., Landi, Stefano, Spinelli, John J., Butrym, Aleksandra, Kumar, Abhishek, Martínez-López, Joaquín, Galimberti, Sara, Sarasquete, María Eugenia, Subocz, Edyta, Iskierka-Jażdżewska, Elzbieta, Giles, Graham G., Rybicka-Ramos, Malwina, Kruszewski, Marcin, Abildgaard, Niels, Verdejo, Francisco García, Sánchez Rovira, Pedro, da Silva Filho, Miguel Inacio, Kadar, Katalin, Razny, Małgorzata, Cozen, Wendy, Pelosini, Matteo, Jurado, Manuel, Bhatti, Parveen, Dudzinski, Marek, Druzd-Sitek, Agnieszka, Orciuolo, Enrico, Li, Yang, Norman, Aaron D, Zaucha, Jan Maciej, Reis, Rui Manuel, Markiewicz, Miroslaw, Rodríguez Sevilla, Juan José, Andersen, Vibeke, Jamroziak, Krzysztof, Hemminki, Kari, Berndt, Sonja I., Rajkumar, Vicent, Mazur, Grzegorz, Kumar, Shaji K., Ludovico, Paula, Nagler, Arnon, Chanock, Stephen J., Dumontet, Charles, Machiela, Mitchell J., Varkonyi, Judit, Camp, Nicola J., Ziv, Elad, Vangsted, Annette Juul, Brown, Elizabeth E., Campa, Daniele, Vachon, Celine M., Netea, Mihai G., Canzian, Federico, Försti, Asta, Sainz, Juan, European Commission, Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Dietmar Hopp Foundation, Federal Ministry of Education and Research (Germany), Fundação para a Ciência e a Tecnologia (Portugal), Clavero, Esther, Sanchez-Maldonado, José Manuel, Macauda, Angélica, Ter Horst, Rob, Sampaio-Marques, Belém, Jurczyszyn, Artur, Clay-Gilmour, Alyssa, Stein, Angelika, Hildebrandt, Michelle A. T., Weinhold, Niels, Buda, Gabriele, García-Sanz, Ramón, Tomczak, Waldemar, Vogel, Ulla, Jerez, Andrés, Zawirska, Daria, Wątek, Marzena, Hofmann, Jonathan N., Landi, Stefano, Spinelli, John J., Butrym, Aleksandra, Kumar, Abhishek, Martínez-López, Joaquín, Galimberti, Sara, Sarasquete, María Eugenia, Subocz, Edyta, Iskierka-Jażdżewska, Elzbieta, Giles, Graham G., Rybicka-Ramos, Malwina, Kruszewski, Marcin, Abildgaard, Niels, Verdejo, Francisco García, Sánchez Rovira, Pedro, da Silva Filho, Miguel Inacio, Kadar, Katalin, Razny, Małgorzata, Cozen, Wendy, Pelosini, Matteo, Jurado, Manuel, Bhatti, Parveen, Dudzinski, Marek, Druzd-Sitek, Agnieszka, Orciuolo, Enrico, Li, Yang, Norman, Aaron D, Zaucha, Jan Maciej, Reis, Rui Manuel, Markiewicz, Miroslaw, Rodríguez Sevilla, Juan José, Andersen, Vibeke, Jamroziak, Krzysztof, Hemminki, Kari, Berndt, Sonja I., Rajkumar, Vicent, Mazur, Grzegorz, Kumar, Shaji K., Ludovico, Paula, Nagler, Arnon, Chanock, Stephen J., Dumontet, Charles, Machiela, Mitchell J., Varkonyi, Judit, Camp, Nicola J., Ziv, Elad, Vangsted, Annette Juul, Brown, Elizabeth E., Campa, Daniele, Vachon, Celine M., Netea, Mihai G., Canzian, Federico, Försti, Asta, and Sainz, Juan
- Abstract
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10−9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10−4−5.79 × 10−14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10−4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 × 10−4) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 × 10−4). We also found that the CD46rs1142469 SNP correlated with numbers of CD19+ B cells, CD19+CD3− B cells, CD5+IgD− cells, IgM− cells, IgD−IgM− cells, and CD4−CD8− PBMCs (p = 4.9 × 10−4−8.6 × 10−4) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2Ars2811710 SNP correlated with levels of CD4+EMCD45RO+CD27− cells (p = 9.3 × 10−4). These results suggest that genetic variants within these six loci influ
- Published
- 2023
29. Identification of novel genetic loci for risk of multiple myeloma by functional annotation
- Author
-
European Commission, National Cancer Institute (US), National Institutes of Health (US), Projekt DEAL, Macauda, Angelica, Briem, Klara, Clay-Gilmour, Alyssa, Cozen, Wendy, Försti, Asta, Giaccherini, Matteo, Corradi, Chiara, Sainz, Juan, Niazi, Yasmeen, Ter Horst, Rob, Li, Yang, Netea, Mihai G., Vogel, Ulla, Hemminki, Kari, Slager, Susan L., Varkonyi, Judit, Andersen, Vibeke, Iskierka-Jazdzewska, Elżbieta, Martínez-López, Joaquín, Zaucha, Jan, Camp, Nicola J., Rajkumar, S. Vincent, Druzd-Sitek, Agnieszka, Bhatti, Parveen, Chanock, Stephen J., Kumar, Shaji K., Subocz, Edyta, Mazur, Grzegorz, Landi, Stefano, Machiela, Mitchell J., Jerez, Andrés, Norman, Aaron D., Hildebrandt, Michelle A. T., Kadar, Katalin, Berndt, Sonja I., Ziv, Elad, Buda, Gabriele, Nagler, Arnon, Dumontet, Charles, Raźny, Malgorzata, Watek, Marzena, Butrym, Aleksandra, Grzasko, Norbert, Dudzinski, Marek, Rybicka-Ramos, Malwina, Matera, Eva-Laure, García-Sanz, Ramón, Goldschmidt, Hartmut, Jamroziak, Krzysztof, Jurczyszyn, Artur, Clavero, Esther, Giles, Graham G., Pelosini, Matteo, Zawirska, Daria, Kruszewski, Marcin, Marques, Herlander, Haastrup, Eva, Sánchez Maldonado, José Manuel, Bertsch, Uta, Rymko, Marcin, Raab, Marc-Steffen, Brown, Elizabeth E., Hofmann, Jonathan N., Vachon, Celine, Campa, Daniele, Canzian, Federico, European Commission, National Cancer Institute (US), National Institutes of Health (US), Projekt DEAL, Macauda, Angelica, Briem, Klara, Clay-Gilmour, Alyssa, Cozen, Wendy, Försti, Asta, Giaccherini, Matteo, Corradi, Chiara, Sainz, Juan, Niazi, Yasmeen, Ter Horst, Rob, Li, Yang, Netea, Mihai G., Vogel, Ulla, Hemminki, Kari, Slager, Susan L., Varkonyi, Judit, Andersen, Vibeke, Iskierka-Jazdzewska, Elżbieta, Martínez-López, Joaquín, Zaucha, Jan, Camp, Nicola J., Rajkumar, S. Vincent, Druzd-Sitek, Agnieszka, Bhatti, Parveen, Chanock, Stephen J., Kumar, Shaji K., Subocz, Edyta, Mazur, Grzegorz, Landi, Stefano, Machiela, Mitchell J., Jerez, Andrés, Norman, Aaron D., Hildebrandt, Michelle A. T., Kadar, Katalin, Berndt, Sonja I., Ziv, Elad, Buda, Gabriele, Nagler, Arnon, Dumontet, Charles, Raźny, Malgorzata, Watek, Marzena, Butrym, Aleksandra, Grzasko, Norbert, Dudzinski, Marek, Rybicka-Ramos, Malwina, Matera, Eva-Laure, García-Sanz, Ramón, Goldschmidt, Hartmut, Jamroziak, Krzysztof, Jurczyszyn, Artur, Clavero, Esther, Giles, Graham G., Pelosini, Matteo, Zawirska, Daria, Kruszewski, Marcin, Marques, Herlander, Haastrup, Eva, Sánchez Maldonado, José Manuel, Bertsch, Uta, Rymko, Marcin, Raab, Marc-Steffen, Brown, Elizabeth E., Hofmann, Jonathan N., Vachon, Celine, Campa, Daniele, and Canzian, Federico
- Abstract
Multiple myeloma (MM) is one of the most common hematological malignancies, accounting for 20% of all newly diagnosed hematological cancers [1]. The most recent data from Cancer Today show that in 2020 the number of new MM cases was 176,404 worldwide
- Published
- 2023
30. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
- Author
-
Università di Pisa, German Cancer Research Center, Dicanio, Marco, Giaccherini, Matteo, Clay-Gilmour, Alyssa, Macauda, Angelica, Sainz, Juan, Machiela, Mitchell J., Rybicka-Ramos, Malwina, Norman, Aaron D., Tyczyńska, Agata, Chanock, Stephen J., Barington, Torben, Kumar, Shaji K., Bhatti, Parveen, Cozen, Wendy, Brown, Elizabeth E., Suska, Anna, Haastrup, Eva K., Orlowski, R. Z., Dudziński, Marek, García-Sanz, Ramón, Kruszewski, Marcin, Martínez-López, Joaquín, Beider, Katia, Iskierka-Jazdzewska, Elżbieta, Pelosini, Matteo, Berndt, Sonja, Raźny, Małgorzata, Jamroziak, Krzysztof, Rajkumar, S. Vincent, Jurczyszyn, Artur, Vangsted, Annette Juul, Garrido, Pilar, Vogel, Ulla, Hofmann, Jonathan N., Petrini, Mario, Butrym, Aleksandra, Slager, Susan L., Ziv, Elad, Subocz, Edyta, Giles, Graham G., Frost Andersen, Niels, Mazur, Grzegorz, Watek, Marzena, Lesueur, Fabienne, Hildebrandt, Michelle A. T., Zawirska, Daria, Hyldahl Ebbesen, Lene, Marques, Herlander, Gemignani, Federica, Dumontet, Charles, Várkonyi, Judit, Buda, Gabriele, Nagler, Arnon, Druzd-Sitek, Agnieszka, Wu, Xifeng, Kadar, Katalin, Camp, Nicola J., Grzasko, Norbert, Waller, Rosalie G., Vachon, Celine, Canzian, Federico, Campa, Daniele, Università di Pisa, German Cancer Research Center, Dicanio, Marco, Giaccherini, Matteo, Clay-Gilmour, Alyssa, Macauda, Angelica, Sainz, Juan, Machiela, Mitchell J., Rybicka-Ramos, Malwina, Norman, Aaron D., Tyczyńska, Agata, Chanock, Stephen J., Barington, Torben, Kumar, Shaji K., Bhatti, Parveen, Cozen, Wendy, Brown, Elizabeth E., Suska, Anna, Haastrup, Eva K., Orlowski, R. Z., Dudziński, Marek, García-Sanz, Ramón, Kruszewski, Marcin, Martínez-López, Joaquín, Beider, Katia, Iskierka-Jazdzewska, Elżbieta, Pelosini, Matteo, Berndt, Sonja, Raźny, Małgorzata, Jamroziak, Krzysztof, Rajkumar, S. Vincent, Jurczyszyn, Artur, Vangsted, Annette Juul, Garrido, Pilar, Vogel, Ulla, Hofmann, Jonathan N., Petrini, Mario, Butrym, Aleksandra, Slager, Susan L., Ziv, Elad, Subocz, Edyta, Giles, Graham G., Frost Andersen, Niels, Mazur, Grzegorz, Watek, Marzena, Lesueur, Fabienne, Hildebrandt, Michelle A. T., Zawirska, Daria, Hyldahl Ebbesen, Lene, Marques, Herlander, Gemignani, Federica, Dumontet, Charles, Várkonyi, Judit, Buda, Gabriele, Nagler, Arnon, Druzd-Sitek, Agnieszka, Wu, Xifeng, Kadar, Katalin, Camp, Nicola J., Grzasko, Norbert, Waller, Rosalie G., Vachon, Celine, Canzian, Federico, and Campa, Daniele
- Abstract
Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits. This feature is particularly relevant in multiple myeloma (MM) because several susceptibility loci that have been identified to date are pleiotropic. Therefore, the aim of this study was to identify novel pleiotropic variants involved in MM risk using 28 684 independent single nucleotide polymorphisms (SNPs) from GWAS Catalog that reached a significant association (P < 5 × 10−8) with their respective trait. The selected SNPs were analyzed in 2434 MM cases and 3446 controls from the International Lymphoma Epidemiology Consortium (InterLymph). The 10 SNPs showing the strongest associations with MM risk in InterLymph were selected for replication in an independent set of 1955 MM cases and 1549 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and 418 MM cases and 147 282 controls from the FinnGen project. The combined analysis of the three studies identified an association between DNAJB4-rs34517439-A and an increased risk of developing MM (OR = 1.22, 95%CI 1.13-1.32, P = 4.81 × 10−7). rs34517439-A is associated with a modified expression of the FUBP1 gene, which encodes a multifunctional DNA and RNA-binding protein that it was observed to influence the regulation of various genes involved in cell cycle regulation, among which various oncogenes and oncosuppressors. In conclusion, with a pleiotropic scan approach we identified DNAJB4-rs34517439 as a potentially novel MM risk locus.
- Published
- 2023
31. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016
- Author
-
Dmoszyńska, Anna, Walter-Croneck, Adam, Pieńkowska-Grela, Barbara, Usnarska-Zubkiewicz, Lidia, Walewski, Jan, Charliński, Grzegorz, Jędrzejczak, Wiesław Wiktor, Wiater, Elżbieta, Lech-Marańda, Ewa, Jamroziak, Krzysztof, Druzd-Sitek, Agnieszka, Dytfeld, Dominik, Komarnicki, Mieczysław, Robak, Tadeusz, Jurczyszyn, Artur, Mańko, Joanna, Skotnicki, Aleksander, Giebel, Sebastian, Czepko, Ryszard, Meder, Janusz, Małkowski, Bogdan, and Giannopoulos, Krzysztof
- Published
- 2016
- Full Text
- View/download PDF
32. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients—Report of the Polish Myeloma Group
- Author
-
Usnarska-Zubkiewicz, L., Dębski, J., Butrym, A., Legieć, W., Hus, M., Dmoszyńska, A., Stella-Hołowiecka, B., Zaucha, J.M., Januszczyk, J., Rymko, M., Torosian, T., Charliński, G., Lech-Marańda, E., Malenda, A., Jurczyszyn, A., Urbańska-Ryś, H., Druzd-Sitek, A., Błońska, D., Urbanowicz, A., Hołojda, J., Pogrzeba, J., Rzepecki, P., Hałka, J., Subocz, E., Becht, R., Zdziarska, B., Dytfeld, D., Nowicki, A., Bołkun, Ł., Kłoczko, J., Knopińska-Posłuszny, W., Zubkiewicz-Kucharska, A., and Kuliczkowski, K.
- Published
- 2016
- Full Text
- View/download PDF
33. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA
- Author
-
Dominik Dytfeld, Jakub Radocha, Roman Hajek, Guldane Cengiz-Seval, Meral Berkac, Daniel Coriu, Benjamin Derman, Andrzej Jakubowiak, Valdas Peceliunas, Gabor Mikkala, Łukasz Bołkun, Dorota Hawrylecka, Sebastian Grosicki, Agata Tyczyńska, Jan Maciej Zaucha, Wanda Knopińska, Grażyna Semeńczuk, Marta Morawska, Krzysztof Giannopoulos, Anna Puła, Marcin Rymko, Grzegorz Charliński, Agnieszka Szeremet, Elżbieta Kalicińska, Lidia Usnarska, Tomasz Wróbel, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Joanna Romejko Jarosińska, Waldemar Sawicki, Anna Waszczuk-Gajda, Adrian Juda, Marek Hus, and Lidia Gil
- Subjects
Oncology ,Hematology - Published
- 2023
34. Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine ( R‐MIV ) in patients with primary CNS lymphoma including recent COVID ‐19 pandemic experience
- Author
-
Ostrowska, Beata, primary, Domanska‐Czyz, Katarzyna, additional, Romejko‐Jarosinska, Joanna, additional, Osowiecki, Michal, additional, Targonski, Lukasz, additional, Poplawska, Lidia, additional, Konecki, Robert, additional, Kotarska, Martyna, additional, Szymanski, Marcin, additional, Borawska, Anna, additional, Swierkowska, Monika, additional, Dabrowska‐Iwanicka, Anna, additional, Druzd‐Sitek, Agnieszka, additional, Paszkiewicz‐Kozik, Ewa, additional, Mroz‐Zycinska, Ewa, additional, Tajer, Joanna, additional, Wojciechowska‐Lampka, Elzbieta, additional, Osiadacz, Wlodzimierz, additional, Rymkiewicz, Grzegorz, additional, Lapinska, Grazyna, additional, Wojewodzka‐Mirocha, Marta, additional, Michalski, Wojciech, additional, and Walewski, Jan, additional
- Published
- 2023
- Full Text
- View/download PDF
35. A Stepwise Screening Protocol for Multiple Myeloma
- Author
-
Morawska, Marta, primary, Dwilewicz-Trojaczek, Jadwiga, additional, Stompór, Tomasz, additional, Ligocki, Piotr, additional, Stopiński, Marek, additional, Sutkowski, Michał, additional, Grząśko, Norbert, additional, Kordecka, Anna, additional, Kordecki, Mariusz, additional, Jurczyszyn, Artur, additional, Dytfeld, Dominik, additional, Wróbel, Tomasz, additional, Jamroziak, Krzysztof, additional, Druzd-Sitek, Agnieszka, additional, Walter-Croneck, Adam, additional, and Giannopoulos, Krzysztof, additional
- Published
- 2023
- Full Text
- View/download PDF
36. Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations
- Author
-
Iwona Hus, Bogusław Machaliński, Mariola Sedzimirska, Jan Maciej Zaucha, Krzysztof Czyżewski, Grzegorz Helbig, Katarzyna Drabko, Adam Fronczak, Olga Zając-Spychała, Ewa Lech-Marańda, Agnieszka Wierzbowska, Krzysztof Kałwak, Agnieszka Druzd-Sitek, Bartłomiej Baumert, Malgorzata Sobczyk-Kruszelnicka, Ewa Lutwin, Dorota Hawrylecka, Katarzyna Smalisz, Tomasz Wróbel, Beata Piątkowska-Jakubas, Kazimierz Hałaburda, Piotr Rzepecki, Marek Hus, Sebastian Giebel, Agnieszka Sobkowiak-Sobierajska, Grzegorz W. Basak, Edyta Cichocka, Aleksandra Krasowska-Kwiecień, Jacek Wachowiak, Anna Czyż, Jan Styczyński, Adam Walter-Croneck, Piotr Boguradzki, Jarosław Dybko, Anna Łojko, Marek Ussowicz, Lidia Gil, Maria Bieniaszewska, Tomasz Szczepański, Jolanta Goździk, Agnieszka Piekarska, and Agnieszka Zaucha-Prażmo
- Subjects
medicine.medical_specialty ,Hematopoietic cell ,business.industry ,Incidence (epidemiology) ,Hematology ,Guideline ,Antimicrobial ,medicine.disease ,Toxoplasmosis ,Vaccination ,Transplantation ,Leukemia ,Oncology ,Medicine ,business ,Intensive care medicine - Abstract
Infections are still a major reason of morbidity and one of the most common causes of death after hematopoietic cell transplantation (HCT). Antimicrobial prophylaxis plays a crucial role in decreasing non-relapse mortality after HCT. The objective of this guideline paper is presentation of current recommendations of antimicrobial prophylaxis for children and adults after hematopoietic cell transplantation, prepared in cooperation of Polish scientific hematological societies. Recommendations were prepared by the working group and finally approved by all 23 Polish transplant centers for children and adults. Existing ECIL (European Conference on Infections in Leukemia) and EBMT (European Society of Blood and Marrow Transplantation) guidelines, as well as results of survey performed among all Polish transplant centers, were the background material for working group. Recommendations are presented in sections dedicated to antibacterial prophylaxis, antifungal prophylaxis, antiviral prophylaxis, as well as prophylaxis of toxoplasmosis and infections with Pneumocystis jiroveci. Recommendations on principles of vaccination against COVID-19 are provided based on the state of knowledge in September 2021. A section on guidelines of environmental prophylaxis is also presented.
- Published
- 2021
37. A polygenic risk score for multiple myeloma risk prediction
- Author
-
Angelica Macauda, Matteo Pelosini, Krzysztof Jamroziak, Mario Petrini, Annette Juul Vangsted, Chiara Piredda, Stephane Minvielle, Marek Dudziński, Hervé Avet-Loiseau, Aleksandra Butrym, Ulla Vogel, Niels Abildgaard, Fabienne Lesueur, Waldemar Tomczak, Vibeke Andersen, Herlander Marques, Daniele Campa, Judit Várkonyi, Rui Manuel Reis, Katalin Kadar, Gabriele Buda, Małgorzata Raźny, Charles Dumontet, Juan Sainz, Anna Suska, Enrico Orciuolo, Agnieszka Druzd-Sitek, Marcin Kruszewski, Daria Zawirska, Niels Frost Andersen, Artur Jurczyszyn, Grzegorz Mazur, Marcin Rymko, Federica Gemignani, Edyta Subocz, Federico Canzian, Katia Beider, Jan Maciej Zaucha, Marzena Wątek, Arnon Nagler, Genomic Epidemiology Group [Heidelberg, Germany] (GEP / DKFZ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), University of Pisa - Università di Pisa, University Hospital of Cracow/Szpital Uniwersytecki w Krakowie [Poland] (SUK), Aarhus University Hospital, Chaim Sheba Medical Center, Sea Hospital [Gdynia, Poland] (SH), Wroclaw Medical University [Wrocław, Pologne] (WMU), Hospices Civils de Lyon (HCL), Holycross Cancer Center of Kelce, Hematology Clinic, Kielce, Institute of Hematology and Transfusion Medicine [Warsaw, Poland] (IHTM), Centre for Genomics and Oncological Research Pfizer [Granada, Spain] (GENYO), University of Granada [Granada]-Andalusian Regional Government [Granada, Spain], Hospital Universitario Virgen de las Nieves [Granada, Spain] (HUVN), Semmelweis University [Budapest], Odense University Hospital (OUH), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Institut Curie [Paris]-MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Teaching Hospital No 1 [Rzeszów, Poland] (TH1), University of Copenhagen = Københavns Universitet (KU), Military Institute of Medicine [Warsaw, Poland] (MIM), Rydygier Specialistic Hospital [Cracow, Poland] (RSH), University of Minho [Braga], Jagiellonian University Medical College [Cracow, Poland] (JUMC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), The National Research Center for Work Environment [Copenhagen, Denmark] (NRCWE), University of Southern Denmark (SDU), ICVS/3B's - PT Government Associate Laboratory [Braga/Guimarães, Portugal] (AL), Barretos Cancer Hospital [São Paulo, Brazil] (BCH), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Bydgoszcz [Bydgoszcz, Poland] (UHB), Medical University of Lublin, N. Copernicus Town Hospital [Torun, Poland] (NCTH), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Bernardo, Elizabeth, Wrocław Medical University, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Universidad de Granada = University of Granada (UGR)-Andalusian Regional Government [Granada, Spain], Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Copenhagen = Københavns Universitet (UCPH), Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
- Subjects
Oncology ,medicine.medical_specialty ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Single-nucleotide polymorphism ,Genome-wide association study ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Risk Factors ,Internal medicine ,Genetics ,medicine ,Genetic predisposition ,Humans ,Genetic Predisposition to Disease ,education ,Genetics (clinical) ,Multiple myeloma ,030304 developmental biology ,Genetic association ,0303 health sciences ,education.field_of_study ,business.industry ,medicine.disease ,Penetrance ,3. Good health ,030220 oncology & carcinogenesis ,Polygenic risk score ,Multiple Myeloma ,business ,Genome-Wide Association Study - Abstract
This work was partially supported by intramural funds of the University of Pisa, DKFZ, and University Hospital of Southern Jutland, Denmark, and by a grant of the French National Cancer Institute (INCA). The authors wish to thank Dr. Dominic Edelmann (Division of Biostatistics, DKFZ) for helpful advice about data analysis., There is overwhelming epidemiologic evidence that the risk of multiple myeloma (MM) has a solid genetic background. Genome-wide association studies (GWAS) have identified 23 risk loci that contribute to the genetic susceptibility of MM, but have low individual penetrance. Combining the SNPs in a polygenic risk score (PRS) is a possible approach to improve their usefulness. Using 2361 MM cases and 1415 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium, we computed a weighted and an unweighted PRS. We observed associations with MM risk with OR = 3.44, 95% CI 2.53-4.69, p = 3.55 x 10(-15) for the highest vs. lowest quintile of the weighted score, and OR = 3.18, 95% CI 2.1 = 34-4.33, p = 1.62 x 10(-13) for the highest vs. lowest quintile of the unweighted score. We found a convincing association of a PRS generated with 23 SNPs and risk of MM. Our work provides additional validation of previously discovered MM risk variants and of their combination into a PRS, which is a first step towards the use of genetics for risk stratification in the general population., University of Pisa, DKFZ, University Hospital of Southern Jutland, Denmark, Institut National du Cancer (INCA) France
- Published
- 2021
38. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
- Author
-
Dicanio, Marco, primary, Giaccherini, Matteo, additional, Clay‐Gilmour, Alyssa, additional, Macauda, Angelica, additional, Sainz, Juan, additional, Machiela, Mitchell J., additional, Rybicka‐Ramos, Malwina, additional, Norman, Aaron D., additional, Tyczyńska, Agata, additional, Chanock, Stephen J., additional, Barington, Torben, additional, Kumar, Shaji K., additional, Bhatti, Parveen, additional, Cozen, Wendy, additional, Brown, Elizabeth E., additional, Suska, Anna, additional, Haastrup, Eva K., additional, Orlowski, Robert Z., additional, Dudziński, Marek, additional, Garcia‐Sanz, Ramon, additional, Kruszewski, Marcin, additional, Martinez‐Lopez, Joaquin, additional, Beider, Katia, additional, Iskierka‐Jazdzewska, Elżbieta, additional, Pelosini, Matteo, additional, Berndt, Sonja I., additional, Raźny, Małgorzata, additional, Jamroziak, Krzysztof, additional, Rajkumar, S. Vincent, additional, Jurczyszyn, Artur, additional, Vangsted, Annette Juul, additional, Collado, Pilar Garrido, additional, Vogel, Ulla, additional, Hofmann, Jonathan N., additional, Petrini, Mario, additional, Butrym, Aleksandra, additional, Slager, Susan L., additional, Ziv, Elad, additional, Subocz, Edyta, additional, Giles, Graham G., additional, Andersen, Niels Frost, additional, Mazur, Grzegorz, additional, Watek, Marzena, additional, Lesueur, Fabienne, additional, Hildebrandt, Michelle A. T., additional, Zawirska, Daria, additional, Ebbesen, Lene Hyldahl, additional, Marques, Herlander, additional, Gemignani, Federica, additional, Dumontet, Charles, additional, Várkonyi, Judit, additional, Buda, Gabriele, additional, Nagler, Arnon, additional, Druzd‐Sitek, Agnieszka, additional, Wu, Xifeng, additional, Kadar, Katalin, additional, Camp, Nicola J., additional, Grzasko, Norbert, additional, Waller, Rosalie G., additional, Vachon, Celine, additional, Canzian, Federico, additional, and Campa, Daniele, additional
- Published
- 2022
- Full Text
- View/download PDF
39. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group
- Author
-
Walter-Croneck, Adam, Grzasko, Norbert, Soroka-Wojtaszko, Maria, Jurczyszyn, Artur, Torosian, Tigran, Rymko, Marcin, Nowicki, Adam, Druzd-Sitek, Agnieszka, Lech-Maranda, Ewa, Madro, Elzbieta, Zielinska, Patrycja, Grygoruk-Wisniowska, Iwona, Blonska, Danuta, Usnarska-Zubkiewicz, Lidia, Potoczek, Stanislaw, Iskierka, Elzbieta, Masternak, Anna, Holojda, Jadwiga, Dawidowska, Dorota, Gawron, Ludmila, Barchnicka, Agnieszka, Olszewska-Szopa, Magdalena, Rybicka, Malwina, Gontarska, Agnieszka, Jachalska, Anna, Rzepecki, Piotr, Subocz, Edyta, Boguradzki, Piotr, Charlinski, Grzegorz, Dzierzak-Mietla, Monika, Wisniewska-Piaty, Katarzyna, Swistek, Wojciech, Kopacz, Agnieszka, Blajer-Olszewska, Beata, Swiderska, Alina, and Dmoszynska, Anna
- Published
- 2014
- Full Text
- View/download PDF
40. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
- Author
-
Jurczyszyn, Artur, Radocha, Jakub, Davila, Julio, Fiala, Mark A., Gozzetti, Alessandro, Grząśko, Norbert, Robak, Paweł, Hus, Iwona, Waszczuk‐Gajda, Anna, Guzicka‐Kazimierczak, Renata, Atilla, Erden, Mele, Giuseppe, Sawicki, Waldemar, Jayabalan, David S., Charliński, Grzegorz, Szabo, Agoston G., Hajek, Roman, Delforge, Michel, Kopacz, Agnieszka, Fantl, Dorotea, Waage, Anders, Avivi, Irit, Rodzaj, Marek, Leleu, Xavier, Richez, Valentine, Knopińska‐Posłuszny, Wanda, Masternak, Anna, Yee, Andrew J., Barchnicka, Agnieszka, Druzd‐Sitek, Agnieszka, Guerrero‐Garcia, Thomas, Liu, Jieqi, Vesole, David H., and Castillo, Jorge J.
- Published
- 2018
- Full Text
- View/download PDF
41. OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma
- Author
-
Jakubowiak, Andrzej, primary, Wrobel, Tomasz, additional, Jamroziak, Krzysztof, additional, Kubicki, Tadeusz, additional, Robak, Pawel, additional, Czyz, Jarosław, additional, Tyczynska, Agata, additional, Druzd-Sitek, Agnieszka, additional, Giannopoulos, Krzysztof, additional, Nowicki, Adam, additional, Lojko-Dankowska, Anna, additional, Matuszak, Magdalena, additional, Gil, Lidia, additional, Pula, Bartosz, additional, Rybka, Justyna, additional, Usnarska-Zubkiewicz, Lidia, additional, Czabak, Olga, additional, Stefka, Andrew, additional, Derman, Benjamin, additional, and Dytfeld, Dominik, additional
- Published
- 2022
- Full Text
- View/download PDF
42. S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
- Author
-
Dytfeld, D., primary, Wróbel, T., additional, Jamroziak, K., additional, Kubicki, T., additional, Robak, P., additional, Walter-Croneck, A., additional, Czyż, J., additional, Tyczyńska, A., additional, Druzd-Sitek, A., additional, Giannopoulos, K., additional, Nowicki, A., additional, Szczepaniak, T., additional, Łojko-Dankowska, A., additional, Matuszak, M., additional, Gil, L., additional, Puła, B., additional, Rybka, J., additional, Majcherek, M., additional, Usnarska-Zubkiewicz, L., additional, Szukalski, L., additional, Końska, A., additional, Zaucha, J. M., additional, Walewski, J., additional, Mikulski, D., additional, Czabak, O., additional, Robak, T., additional, Grzybowska, U., additional, Lahoud, O. B., additional, Zonder, J. A., additional, Griffith, K., additional, Stefka, A., additional, Major, A., additional, Derman, B. A., additional, and Jakubowiak, A. J., additional
- Published
- 2022
- Full Text
- View/download PDF
43. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma
- Author
-
Ewa Paszkiewicz‐Kozik, Wojciech Michalski, Michał Taszner, Monika Mordak‐Domagała, Joanna Romejko‐Jarosińska, Wanda Knopińska‐Posłuszny, Jacek Najda, Anna Borawska, Monika Chełstowska, Monika Świerkowska, Anna Dąbrowska‐Iwanicka, Agata Malenda, Agnieszka Druzd‐Sitek, Robert Konecki, Beata Kumiega, Michał Osowiecki, Beata Ostrowska, Tomasz Szpila, Marcin Szymański, Łukasz Targoński, Katarzyna Domańska‐Czyż, Lidia Popławska, Sebastian Giebel, Andrzej Lange, Andrzej Pluta, Jan Maciej Zaucha, Grzegorz Rymkiewicz, and Jan Walewski
- Subjects
Salvage Therapy ,Lymphoma, Non-Hodgkin ,Cytarabine ,Hematology ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Ifosfamide ,Lymphoma, Large B-Cell, Diffuse ,Neoplasm Recurrence, Local ,Rituximab ,Aged ,Etoposide - Abstract
The efficacy of salvage treatment of diffuse large B-cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety of ofatumumab with iphosphamide, etoposide and cytarabine (O-IVAC) was evaluated in a single-arm study. Dosing was modified for elderly patients. Patients received up to six cycles of treatment. The primary end-point was the overall response rate (ORR). Patients were evaluated every two cycles and then six and 12 months after treatment. Other end-points included progression-free survival (PFS), event-free survival (EFS), overall survival (OS) and safety. Seventy-seven patients received salvage treatment with O-IVAC. The average age was 56.8 years; 39% had an Eastern Cooperative Oncology Group (ECOG) performance status of at least 3; 78% had disease of Ann Arbor stage 3 or 4; 58% received one or more prior salvage therapies. The ORR for O-IVAC was 54.5%. The median duration of study follow-up was 70 months. The median PFS and EFS were 16.3 months each. The median OS was 22.7 months. Age, ECOG performance status and the number of prior therapy lines were independent predictors of survival. Treatment-related mortality was 15.5%. O-IVAC showed a high response rate in a difficult-to-treat population and is an attractive treatment to bridge to potentially curative therapies.
- Published
- 2022
44. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
- Author
-
Paszkiewicz‐Kozik, Ewa, primary, Michalski, Wojciech, additional, Taszner, Michał, additional, Mordak‐Domagała, Monika, additional, Romejko‐Jarosińska, Joanna, additional, Knopińska‐Posłuszny, Wanda, additional, Najda, Jacek, additional, Borawska, Anna, additional, Chełstowska, Monika, additional, Świerkowska, Monika, additional, Dąbrowska‐Iwanicka, Anna, additional, Malenda, Agata, additional, Druzd‐Sitek, Agnieszka, additional, Konecki, Robert, additional, Kumiega, Beata, additional, Osowiecki, Michał, additional, Ostrowska, Beata, additional, Szpila, Tomasz, additional, Szymański, Marcin, additional, Targoński, Łukasz, additional, Domańska‐Czyż, Katarzyna, additional, Popławska, Lidia, additional, Giebel, Sebastian, additional, Lange, Andrzej, additional, Pluta, Andrzej, additional, Zaucha, Jan Maciej, additional, Rymkiewicz, Grzegorz, additional, and Walewski, Jan, additional
- Published
- 2022
- Full Text
- View/download PDF
45. A Stepwise Screening Protocol for Multiple Myeloma
- Author
-
Marta Morawska, Jadwiga Dwilewicz-Trojaczek, Tomasz Stompór, Piotr Ligocki, Marek Stopiński, Michał Sutkowski, Norbert Grząśko, Anna Kordecka, Mariusz Kordecki, Artur Jurczyszyn, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Adam Walter-Croneck, and Krzysztof Giannopoulos
- Subjects
General Medicine - Abstract
Background: Monoclonal gammopathies and multiple myeloma should be screened in the primary care setting. Methods: The screening strategy consisted of an initial interview supported with the analysis of basic laboratory test results and the increasing laboratory workload in the following steps was developed based on characteristics of patients with multiple myeloma. Results: The developed 3-step screening protocol includes evaluation of myeloma-related bone disease, two renal function markers, and three hematologic markers. In the second step, the erythrocyte sedimentation rate (ESR) and the level of C-reactive protein (CRP) were cross-tabulated to identify persons qualifying for confirmation of the presence of monoclonal component. Patients with diagnosed monoclonal gammopathy should be referred to a specialized center to confirm the diagnosis. The screening protocol testing identified 900 patients with increased ESR and normal level of CRP and 94 of them (10.4%) had positive immunofixation. Conclusions: The proposed screening strategy resulted in an efficient diagnosis of monoclonal gammopathy. The stepwise approach rationalized the diagnostic workload and cost of screening. The protocol would support primary care physicians, standardizing the knowledge about the clinical manifestation of multiple myeloma and the method of evaluation of symptoms and diagnostic test results.
- Published
- 2023
46. High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
- Author
-
Joanna Romejko-Jarosinska, Beata Ostrowska, Anna Dabrowska-Iwanicka, Katarzyna Domanska-Czyz, Grzegorz Rymkiewicz, Ewa Paszkiewicz-Kozik, Robert Konecki, Anna Borawska, Agnieszka Druzd-Sitek, Elzbieta Lampka, Wlodzimierz Osiadacz, Michal Osowiecki, Lidia Popławska, Monika Swierkowska, Lukasz Targonski, Joanna Tajer, Grazyna Lapinska, Malwina Smorczewska, and Jan Walewski
- Subjects
Adult ,Male ,Multidisciplinary ,Lymphoma, B-Cell ,Middle Aged ,Cardiotoxicity ,Methotrexate ,Doxorubicin ,Vincristine ,Positron Emission Tomography Computed Tomography ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Lymphoma, Large B-Cell, Diffuse ,Neoplasm Recurrence, Local ,Rituximab ,Cyclophosphamide ,Follow-Up Studies - Abstract
Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85–95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggressive B-cell lymphoma GMALL/B-ALL/NHL2002 including 6 cycles of alternating immunochemotherapy with intermediate-dose methotrexate in each cycle, and reduced total doxorubicin dose (100 mg/m2 for whole treatment). Majority of patients (77%) received consolidative radiotherapy. A median (range) age of patients was 30 (18–59) years, and 60% were female. With a median (range) follow up of 9 (1–17) years, 5-year overall survival (OS) and 5-year progression free survival (PFS) were 94% and 92%, respectively. Positron emission tomography—computed tomography (PET-CT) results at the end of chemotherapy were predictive for outcome: OS and PFS at 5 year were 96% and 94% in PET-CT negative patients, respectively, and 70% and 70% in PET-CT-positive patients (p = 0.004 for OS, p = 0.01 for PFS). Eight (6%) patients had recurrent/refractory disease, however, no central nervous system (CNS) relapse was observed. Acute toxicity included pancytopenia grade 3/4, neutropenic fever, and treatment related mortality rate of 0.8%. Second malignancies and late cardiotoxicity occurred in 2.4% and 2.4% of patients, respectively. Intensive alternating immunochemotherapy protocol GMALL/B-ALL/NHL2002 is curative for more than 90% of PMBL patients and late toxicity in young patients is moderated. The attenuated dose of doxorubicin and intermediate dose of methotrexate may contribute to low incidence of late cardiotoxicity and effective CNS prophylaxis.
- Published
- 2021
47. Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations
- Author
-
Styczynski, Jan, primary, Piekarska, Agnieszka, additional, Zaucha-Prażmo, Agnieszka, additional, Zaucha, Jan Maciej, additional, Zając-Spychała, Olga, additional, Wróbel, Tomasz, additional, Wierzbowska, Agnieszka, additional, Walter-Croneck, Adam, additional, Wachowiak, Jacek, additional, Ussowicz, Marek, additional, Szczepański, Tomasz, additional, Sobkowiak-Sobierajska, Agnieszka, additional, Sobczyk-Kruszelnicka, Małgorzata, additional, Smalisz, Katarzyna, additional, Sędzimirska, Mariola, additional, Rzepecki, Piotr, additional, Piątkowska-Jakubas, Beata, additional, Łojko, Anna, additional, Lutwin, Ewa, additional, Lech-Marańda, Ewa, additional, Machaliński, Bogusław, additional, Krasowska-Kwiecień, Aleksandra, additional, Kałwak, Krzysztof, additional, Hus, Marek, additional, Hus, Iwona, additional, Helbig, Grzegorz, additional, Hawrylecka, Dorota, additional, Hałaburda, Kazimierz, additional, Goździk, Jolanta, additional, Giebel, Sebastian, additional, Fronczak, Adam, additional, Dybko, Jarosław, additional, Druzd-Sitek, Agnieszka, additional, Drabko, Katarzyna, additional, Czyżewski, Krzysztof, additional, Czyż, Anna, additional, Cichocka, Edyta, additional, Boguradzki, Piotr, additional, Bieniaszewska, Maria, additional, Baumert, Bartłomiej, additional, Basak, Grzegorz, additional, and Gil, Lidia, additional
- Published
- 2021
- Full Text
- View/download PDF
48. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
- Author
-
Jurczyszyn, Artur, Grzasko, Norbert, Gozzetti, Alessandro, Czepiel, Jacek, Cerase, Alfonso, Hungria, Vania, Crusoe, Edvan, Silva Dias, Ana Luiza Miranda, Vij, Ravi, Fiala, Mark A., Caers, Jo, Rasche, Leo, Nooka, Ajay K., Lonial, Sagar, Vesole, David H., Philip, Sandhya, Gangatharan, Shane, Druzd-Sitek, Agnieszka, Walewski, Jan, Corso, Alessandro, Cocito, Federica, Vekemans, Marie-Christine M., Atilla, Erden, Beksac, Meral, Leleu, Xavier, Davila, Julio, Badros, Ashraf, Aneja, Ekta, Abildgaard, Niels, Kastritis, Efstathios, Fantl, Dorotea, Schutz, Natalia, Pika, Tomas, Butrym, Aleksandra, Olszewska-Szopa, Magdalena, Usnarska-Zubkiewicz, Lidia, Usmani, Saad Z., Nahi, Hareth, Chim, Chor S, Shustik, Chaim, Madry, Krzysztof, Lentzsch, Suzanne, Swiderska, Alina, Helbig, Grzegorz, Guzicka-Kazimierczak, Renata, Lendvai, Nikoletta, Waage, Anders, Andersen, Kristian T., Murakami, Hirokazu, Zweegman, Sonja, and Castillo, Jorge J.
- Published
- 2016
- Full Text
- View/download PDF
49. A polygenic risk score for multiple myeloma risk prediction
- Author
-
Canzian, Federico, primary, Piredda, Chiara, additional, Macauda, Angelica, additional, Zawirska, Daria, additional, Andersen, Niels Frost, additional, Nagler, Arnon, additional, Zaucha, Jan Maciej, additional, Mazur, Grzegorz, additional, Dumontet, Charles, additional, Wątek, Marzena, additional, Jamroziak, Krzysztof, additional, Sainz, Juan, additional, Várkonyi, Judit, additional, Butrym, Aleksandra, additional, Beider, Katia, additional, Abildgaard, Niels, additional, Lesueur, Fabienne, additional, Dudziński, Marek, additional, Vangsted, Annette Juul, additional, Pelosini, Matteo, additional, Subocz, Edyta, additional, Petrini, Mario, additional, Buda, Gabriele, additional, Raźny, Małgorzata, additional, Gemignani, Federica, additional, Marques, Herlander, additional, Orciuolo, Enrico, additional, Kadar, Katalin, additional, Jurczyszyn, Artur, additional, Druzd-Sitek, Agnieszka, additional, Vogel, Ulla, additional, Andersen, Vibeke, additional, Reis, Rui Manuel, additional, Suska, Anna, additional, Avet-Loiseau, Hervé, additional, Kruszewski, Marcin, additional, Tomczak, Waldemar, additional, Rymko, Marcin, additional, Minvielle, Stephane, additional, and Campa, Daniele, additional
- Published
- 2021
- Full Text
- View/download PDF
50. Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
- Author
-
Grzasko, Norbert, primary, Charlinski, Grzegorz, additional, Morawska, Marta, additional, Kicinski, Pawel, additional, Waszczuk-Gajda, Anna, additional, Drozd-Sokolowska, Joanna, additional, Subocz, Edyta, additional, Blonska, Danuta, additional, Razny, Malgorzata, additional, Druzd-Sitek, Agnieszka, additional, Holojda, Jadwiga, additional, Swiderska, Alina, additional, Usnarska-Zubkiewicz, Lidia, additional, Masternak, Anna, additional, and Giannopoulos, Krzysztof, additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.